# TRAMPOLINE PHARMA, INC.: Development of a Universal Next Generation T Cell Receptor Cancer Therapy: Preclinical Proof-of-Concept and Optimization

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | TRAMPOLINE PHARMA, INC. |
| Location | AURORA, CO |
| Project | Development of a Universal Next Generation T Cell Receptor Cancer Therapy: Preclinical Proof-of-Concept and Optimization |
| Project number | 1R43CA310292-01 |
| Mechanism | R43 |
| Institute | National Cancer Institute |
| Award | $398,039 |
| Awarded | 2026-09-10 |
| Project period | 2026-09-10 to 2027-08-31 |
| UEI | QAE3GETX9Z88 |

## Why this score
- Award of $398,039.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11315490). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.